FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Instagram Outage Disrupts Thousands of U.S. Users 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
 - EconoTimes)
NEW YORK, March 22, 2018 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Henry Schein, Inc. (NASDAQ:HSIC) who purchased shares between March 7, 2013 and February 12, 2018. The action, which was filed in the United States District Court for the Eastern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Henry Schein was engaging in unethical, anti-competitive behavior through agreements with Benco Dental Supply Company and Patterson Companies, Inc., in violation of United States antitrust laws; (2) Henry Schein engaged in such behavior, in part, to help maintain profitability in a consolidating health care industry; (3) these violations of U.S. antitrust laws would result in heightened scrutiny by the federal government and a lawsuit filed by the Federal Trade Commission (“FTC”); (4) Henry Schein failed to maintain adequate internal controls; and (5) as a result, defendants' statements about Henry Schein’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders have until May 7, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/henry-schein-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
